ArticleOncology research2025
Construction of a Prognostic Model of Prostate Cancer Based on Immune and Metabolic Genes and Experimental Validation of the Gene AK5.
Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Despite the fact that prostate cancer is one of the most common tumors in men, this study intends to evaluate the predictive significance of immune and metabolic genes in prostate cancer using multi-omics data and experimental validation. Methods: The research developed and validated a prognostic model utilizing The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, integrating immune and metabolic gene sets. Additionally, the prognostic gene Adenylate Kinase 5 (AK5) was analyzed in prostate cancer tissue microarrays from Ruijin Hospital. The functional role of the AK5 gene was validated through knockdown and overexpression experiments in four prostate cancer cell lines, employing cell proliferation assays, colony formation assays, and both xenograft models in nude mice and patient-derived xenograft models. Results: This research developed a prognostic model comprising ten genes, which was validated across multiple datasets for its predictive efficacy. Experimental results indicated that AK5 is significantly expressed in prostate cancer and facilitates tumor proliferation; knockdown of AK5 inhibited cell colony formation and growth of subcutaneous xenografts in nude mice, while AK5 inhibitors significantly reduced tumor volume in patient-derived xenografts. Conclusion: This study constructed a prognostic model with clinical potential and preliminarily confirmed the oncogenic role of AK5 in prostate cancer. The findings indicate that focusing on the immunological metabolic axis and the AK5 gene may offer novel approaches for prostate cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.